US equities |
MU $965.50 ▲+3.96% META $610.20 ▼-1.61% TSLA $401.46 ▼-1.47% SPCX $143.45 ▼-3.45% NVDA $216.36 ▼-0.72% SNDK $1,373.65 ▲+5.27% GOOGL $323.06 ▲+0.77% SKHY $163.53 ▲+12.50%
FinancialContent

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

21.20 -0.24 (-1.12%)
Delayed Quote Updated: 2:15 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
News headline image
Amneal to Report Third Quarter 2026 Results on November 3, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces FDA Approval and Launch of Lanreotide Injection
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
From Kaskela Law
Via Business Wire
News headline image
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Second Quarter 2026 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report Second Quarter 2026 Results on July 30, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports First Quarter 2026 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
From Kashiv BioSciences, LLC
Via Business Wire
News headline image
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report First Quarter 2026 Results on May 1, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Upcoming Investor Conference
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Represents second complex respiratory therapeutic product approval in Q4 2025 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Upcoming Investor Conferences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Iohexol Injection
First-to-market complex injectable with expected launch in Q1 2026 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
< Previous 1 2 3 Next >